Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: August 15, 2022
Accepted: January 16, 2023
Published online: March 06, 2023

Number of Print Pages: 9
Number of Figures: 6
Number of Tables: 0

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Abstract

Introduction: A cerebral vasospasm (CVSP) is a potent vasoconstriction of the cerebral vasculature and the primary cause of morbidity and mortality following a subarachnoid hemorrhage. The middle cerebral artery (MCA) is commonly affected by CVSPs. Concomitant administration of dantrolene and nimodipine synergistically reduces vasospasms in aortic rings from Sprague Dawley rats. To determine if the effects observed in the systemic vasculature extend to the cerebral circulation, we investigated the effect of intravenous administration of dantrolene (2.5 mg/kg) and nimodipine (1 mg/kg and 2 mg/kg) on MCA blood flow velocity (BFV) 7 days after the induction of CVSPs. Methods: Vasospasms were induced by bathing the left common carotid artery with autologous whole blood. Age-matched sham rats were used as controls. BFV, mean arterial pressure (MAP), and heart rate (HR) were measured with a PeriFlux 5000 Laser Doppler System, and a CODA non-invasive blood pressure system, before and after administering the drugs. Morphometric evaluations were also performed to assess vascular alterations. Results: BFV was reduced by 37% with dantrolene alone (n = 6, p ≤ 0.05) and by 27% with 2 mg/kg nimodipine (n = 6, p < 0.05), while it was not affected by 1 mg/kg nimodipine. The combination of 1 mg/kg nimodipine with dantrolene, however, decreased BFV by 35% (from 435.70 ± 21.53 to 284.30 ± 23.13 perfusion units, n = 7, p ≤ 0.05). A similar reduction (31%) was obtained with dantrolene and 2 mg/kg nimodipine (from 536.00 ± 32.61 to 367.80 ± 40.93 perfusion units, n = 6, p ≤ 0.05). Neither MAP nor HR was affected by dantrolene or nimodipine alone. The combination of dantrolene with 2 mg/kg nimodipine, however, decreased MAP and increased HR. Furthermore, 7 days after the induction of vasospasms, lumen area of the left common carotid artery decreased, whereas media thickness and the wall-to-lumen ratio increased when compared to contralateral controls. The latter finding suggests that vascular remodeling was present at this stage. Conclusion: Altogether, our results indicate that 2.5 mg/kg dantrolene significantly reduces BFV in the MCA without altering systemic hemodynamic parameters to a similar extent than the highest dose of nimodipine or the combination of dantrolene and the lowest dose of nimodipine. Therefore, dantrolene may provide a promising alternative to lower the risk, or partially revert, CVSP.

© 2023 S. Karger AG, Basel

References Findlay JM, Nisar J, Darsaut T. Cerebral vasospasm: a review. Can J Neurol Sci. 2016;43(1):15–32. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: a report from the American heart association. Circulation. 2020;141(9):e139–e596. Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985;16(4):562–72. Navedo MF, Takeda Y, Nieves-Cintrón M, Molkentin JD, Santana LF. Elevated Ca2+ sparklet activity during acute hyperglycemia and diabetes in cerebral arterial smooth muscle cells. Am J Physiol Cell Physiol. 2010;298(2):C211–20. Dabertrand F, Nelson MT, Brayden JE. Ryanodine receptors, calcium signaling, and regulation of vascular tone in the cerebral parenchymal microcirculation. Microcirculation. 2013;20(4):307–16. Mahajan C. Chapter 18 - aneurysmal subarachnoid hemorrhage. In: Prabhakar H, editor. Essentials of neuroanesthesia Academic Press; 2017. p. 315–37. Dorhout Mees SM, Rinkel GJE, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2000;(2):CD000277. Huang Y, Lei C, Xie W, Yan L, Wang Y, Yuan S, et al. Oxidation of ryanodine receptors promotes Ca2+ leakage and contributes to right ventricular dysfunction in pulmonary hypertension. Hypertension. 2021;77(1):59–71. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene: a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59(4):364–73. Aslan A, Cemek M, Buyukokuroglu ME, Altunbas K, Bas O, Yurumez Y, et al. Dantrolene can reduce secondary damage after spinal cord injury. Eur Spine J. 2009;18(10):1442–51. Neylon CB, Richards SM, Larsen MA, Agrotis A, Bobik A. Multiple types of ryanodine receptor/Ca2+ release channels are expressed in vascular smooth muscle. Biochem Biophys Res Commun. 1995;215(3):814–21. Muehlschlegel S, Carandang R, Hall W, Kini N, Izzy S, Garland B, et al. Dantrolene for cerebral vasospasm after subarachnoid haemorrhage: a randomised double blind placebo-controlled safety trial. J Neurol Neurosurg Psychiatry. 2015;86(9):1029–35. Ortiz Torres MJ, Jahngir M, Qualls K, Litofsky NS, Nattanmai P, Qureshi AI. Intra-arterial dantrolene for refractory cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. World Neurosurg. 2019;125:247–52. Crespo MJ, Roman M, Matias J, Morales M, Torres H, Quidgley J. Synergistic effects of dantrolene and nimodipine on the phenylephrine-induced contraction and ACh-induced relaxation in aortic rings from diabetic rats. Int J Endocrinol. 2018;2018:9790303. Román M, Ramírez JM, Morales M, Crespo MJ. Significant reduction of vascular reactivity with dantrolene and nimodipine in diabetic rats: a potential approach to cerebral vasospasm management in diabetes. Pharmacol Rep. 2020;72(1):126–34. Román M, García L, Morales M, Crespo MJ. The combination of dantrolene and nimodipine effectively reduces 5-HT-induced vasospasms in diabetic rats. Sci Rep. 2021 May 10;11(1):9852. Lin HP, Zheng YQ, Zhou ZP, Wang GX, Guo PF. Ryanodine receptor antagonism alleviates skeletal muscle ischemia reperfusion injury by modulating TNF-α and IL-10. Clin Hemorheol Microcirc. 2018;70(1):51–8. Lee CK, Choi JS, Choi DH. Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatin. Indian J Pharmacol. 2012;44(5):624–8. Cho YA, Choi JS, Burm JP. Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. Pharmacol Rep. 2011;63(4):1066–73. Okada T, Harada T, Bark DH, Mayberg MR. A rat femoral artery model for vasospasm. Neurosurgery. 1990 Sep;27(3):349–56. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to Image J: 25 years of image analysis. Nat Methods. 2012 Jul;9(7):671–5. Salomone S, Soydan G, Moskowitz MA, Sims JR. Inhibition of cerebral vasoconstriction by dantrolene and nimodipine. Neurocrit Care. 2009;10(1):93–102. Dabus G, Nogueira RG. Current options for the management of aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm: a comprehensive review of the literature. Interv Neurol. 2013;2(1):30–51. Hill MD. Stroke and diabetes mellitus. Handb Clin Neurol. 2014;126:167–74. Vaithianathan T, Narayanan D, Asuncion-Chin MT, Jeyakumar LH, Liu J, Fleischer S, et al. Subtype identification and functional characterization of ryanodine receptors in rat cerebral artery myocytes. Am J Physiol Cell Physiol. 2010;299(2):C264–78. Pierobon N, Renard-Rooney DC, Gaspers LD, Thomas AP. Ryanodine receptors in liver. J Biol Chem. 2006;281(45):34086–95. Tuttolomondo A, Daidone M, Pinto A. Endothelial dysfunction and inflammation in ischemic stroke pathogenesis. Curr Pharm Des. 2020;26(34):4209–19. Wang JL, Li XN, Zhang YH, Li X, Yang YL. Evaluation function of transcranial two-dimensional and color Doppler ultrasonography (TCCS) for patients with different degrees of cerebral vasospasm before and after the nimodipine treatment. Eur Rev Med Pharmacol Sci. 2017;21(11):2757–63. Buggy DJ, Asher MJ, Lambert DG. Nimodipine premedication and induction dose of propofol. Anesth Analg. 2000 Feb;90(2):445–9. 10648337 Kraaier V, van Huffelen AC, Wieneke GH, Hesselink JM. Nimodipine tested in a human model of cerebral ischaemia. Electroencephalographic and transcranial Doppler ultrasound investigations in normal subjects during standardized hyperventilation. Eur J Clin Pharmacol. 1991;40(1):17–21. Muehlschlegel S, Rordorf G, Bodock M, Sims JR. Dantrolene mediates vasorelaxation in cerebral vasoconstriction: a case series. Neurocrit Care. 2009;10(1):116–21. Muehlschlegel S, Sims JR. Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit. Neurocrit Care. 2009;10(1):103–15. Muehlschlegel S, Rordorf G, Sims J. Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study. Stroke. 2011;42(5):1301–6. Canova D, Roatta S, Micieli G, Bosone D. Cerebral oxygenation and haemodynamic effects induced by nimodipine in healthy subjects. Funct Neurol. 2012 Jul–Sep;27(3):169–76. Heistad DD. What’s new in the cerebral microcirculation? Microcirculation. 2001;8(6):365–75. Wahl M, Schilling L. Regulation of cerebral blood flow--a brief review. Acta Neurochir Suppl. 1993;59:3–10. Silverman A, Petersen NH. Physiology, cerebral autoregulation. StatPearls.Treasure island (FL): StatPearls Publishing; 2022 Jan. [Updated 2022 Feb 16]. Ahmed N, Näsman P, Wahlgren NG. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke. 2000;31(6):1250–5. Langley MS, Sorkin EM. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs. 1989;37(5):669–99. Fischer C, Goldberg J, Vulcu S, Wagner F, Schöni D, Söll N, et al. Nimodipine-induced blood pressure changes can predict delayed cerebral ischemia. Front Neurol. 2019;10:1161. Majidi S, Grigoryan M, Tekle WG, Qureshi AI. Intra-arterial dantrolene for refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2012;17(2):245–9. Ma Y, Qiao G, Yin Y, Zhang Y, Yu Y, Yu X. Protective effects of astragaloside IV on delayed cerebral vasospasm in an experimental rat model of subarachnoid hemorrhage. World Neurosurg. 2018;118:e443–48. Megyesi JF, Findlay JM, Vollrath B, Cook DA, Chen MH. In vivo angioplasty prevents the development of vasospasm in canine carotid arteries. Pharmacological and morphological analyses. Stroke. 1997;28(6):1216–24. Borel CO, McKee A, Parra A, Haglund MM, Solan A, Prabhakar V, et al. Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage. Stroke. 2003;34(2):427–33. Guvenc Tuna B, Lachkar N, de Vos J, Bakker ENTP, VanBavel E. Cerebral artery remodeling in rodent models of subarachnoid hemorrhage. J Vasc Res. 2015;52(2):103–15. Article / Publication Details

First-Page Preview

Received: August 15, 2022
Accepted: January 16, 2023
Published online: March 06, 2023

Number of Print Pages: 9
Number of Figures: 6
Number of Tables: 0

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA